Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,669 recruiting studies in this area right now.
By phase
- Not applicable9,830
- Phase 24,462
- Phase 12,741
- Phase 1/Phase 21,687
- Phase 31,405
- Phase 2/Phase 3281
- Phase 4263
Top conditions
- Breast Cancer1,229
- Cancer659
- Prostate Cancer657
- Colorectal Cancer496
- Lung Cancer428
- Ovarian Cancer338
- Multiple Myeloma329
- Gastric Cancer300
- Pancreatic Cancer296
- Acute Myeloid Leukemia293
- Hepatocellular Carcinoma284
- Solid Tumor258
- Advanced Solid Tumor256
- Cervical Cancer232
- Head and Neck Cancer229
- Endometrial Cancer205
- Advanced Solid Tumors195
- Esophageal Cancer193
Leading sponsors
- M.D. Anderson Cancer Center451
- Fudan University311
- Memorial Sloan Kettering Cancer Center289
- Sun Yat-sen University289
- National Cancer Institute (NCI)288
- Mayo Clinic238
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca132
- University Health Network, Toronto125
Where studies are running
- California1,425
- Texas641
- Arizona513
- Florida446
- Alabama420
- New York412
- Massachusetts340
- Maryland328
- New Jersey268
- Pennsylvania241
Recruiting studies20,669 total
- NCT05272384RecruitingPhase 1
Testing nivolumab plus ASTX727 for hard-to-treat lymphoma
This Phase 1 study tests whether adding ASTX727 to nivolumab can shrink relapsed or refractory B-cell lymphomas that have come back or did not respond to treatment. It also aims to find a safe dosing plan and see early signs of benefit in certain lymphoma types.
Birmingham, AlabamaAges 18 years+ - NCT05272696RecruitingPhase 2
Pembrolizumab plus chemo before treatment for advanced head and neck cancer
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
Guangzhou, GuangdongAges 18–70 - NCT05272826RecruitingPhase 2
New, untreated myeloma study using four medicines
This Phase 2 trial tests a combination of medicines (iberdomide, bortezomib, dexamethasone, and adding isatuximab) for people with newly diagnosed multiple myeloma who cannot have a transplant. The goal is to improve disease control while checking safety in older adults who can take pills and attend frequent visits.
Edmonton, AlbertaAges 65 years+ - NCT05274048RecruitingPhase 1
Neratinib plus antibody-drug for HER2-positive stomach or esophagus cancer
This early-phase trial tests neratinib together with an antibody-drug to treat advanced HER2-positive gastro-esophageal (stomach/esophagus) cancer that can’t be removed by surgery. It’s for people whose cancer has progressed after at least one HER2-targeted treatment, aiming to shrink tumors and improve outcomes.
Palo Alto, CaliforniaAges 18 years+ - NCT05274919Recruiting
Brain tumor MRI pattern study to map tumor genetics
This study uses special “pattern mapping” from brain MRI scans to see whether MRI images reflect a brain tumor’s genetic type. It may help doctors better match MRI findings to tumor characteristics using scans they may already need for diagnosis.
LeidenAges 18 years+ - NCT05275881Recruiting
Virtual reality during procedures for young blood or cancer patients
This trial tests whether using virtual reality (VR) during certain procedures can make them easier for children, teens, and young adults with blood or cancer-related conditions. Participants must be able to safely use a VR headset and be willing to take part.
PoitiersAges 7–24 - NCT05276037Recruiting
PET/CT scan to guide liver transplant decisions in liver cancer
This trial studies how a whole-body PET/CT scan using a “tracer” called 18F-FDG can help decide which people with liver cancer (HCC) may benefit from a liver transplant. It may help the transplant team better sort out who is likely to do well after transplant.
AntwerpAges 18–80 - NCT05278052RecruitingPhase 3
Maintenance therapy alone versus radiation plus maintenance for lung cancer
This trial compares standard maintenance treatment versus adding focused radiation to remaining limited (oligometastatic) spots in the body after initial chemotherapy. It aims to see whether treating those limited spots with radiation can improve outcomes without unacceptable side effects.
Mumbai, MaharashtraAges 18–99 - NCT05277844RecruitingPhase 2
Radiation plus targeted pill vs pill alone for EGFR/ALK-NSCLC
This study tests whether adding focused radiation to a targeted cancer pill works better than the pill by itself. It is for people with advanced non-small cell lung cancer (NSCLC) whose tumor has an EGFR or ALK/ROS driver mutation and who have not gotten worse after starting the targeted pill.
Mumbai, MaharashtraAges 18–99 - NCT05277935Recruiting
Wearable activity tracking for hormone-positive metastatic breast cancer
This study tests whether using a wearable watch and smartphone app to track activity and fitness can help monitor health in people with hormone receptor–positive, HER2-negative metastatic breast cancer while they take standard hormone therapy plus palbociclib. It mainly requires that you are already on these medicines for at least three months and can use the devices reliably.
Rio de JaneiroAges 18 years+ - NCT05278715RecruitingPhase 2
New treatment plan for optic pathway glioma in children
This Phase 2 trial tests a modified chemotherapy treatment plan for children and young people with optic pathway glioma, aiming to shrink tumor and improve eye/brain symptoms. You may be able to join if your diagnosis is confirmed and your body can safely handle treatment.
BeijingAges 3 months–21 years - NCT05280314RecruitingPhase 2
Immunotherapy before and after surgery for stage III melanoma or throat cancer
This trial tests two immunotherapy medicines given before surgery and again after surgery to help control the cancer and improve outcomes. It studies people with resectable (operable) stage III melanoma or certain stage III/IVA throat cancers.
New Haven, ConnecticutAges 18 years+ - NCT05281003RecruitingPhase 2
Pembrolizumab plus chemo before surgery for esophageal cancer
This trial tests whether giving pembrolizumab (an immune therapy) plus chemotherapy before surgery can improve outcomes for people with locally advanced, operable esophageal squamous cell carcinoma. It may help shrink the tumor and improve the chance of successful surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05281731Recruiting
Ultrasound-guided “sonobiopsy” for new brain tumor diagnosis
This trial tests a new way to take a tiny tissue sample from a suspected glioblastoma using ultrasound, to improve noninvasive detection. You may be able to get this targeted sample while you’re already planning surgery for tumor removal.
St Louis, MissouriAges 18 years+ - NCT05281406RecruitingPhase 2
Extra chemotherapy if tumor DNA stays positive after osimertinib
This Phase 2 trial tests whether adding chemotherapy can help people with EGFR-mutated lung cancer when their cancer-related blood test (liquid biopsy for EGFR DNA) is still positive after 3–4 weeks of starting osimertinib. It may help slow the cancer for longer by treating any remaining disease activity.
BerlinAges 18 years+ - NCT05281237Recruiting
Microwave ablation for small early lung cancer nodules
This trial studies a flexible “microwave heating” probe placed through the airways to treat small lung cancer nodules. It may help some patients avoid more invasive treatment by destroying the tumor during a bronchoscopy procedure.
Boston, MassachusettsAges 22 years+ - NCT05281809RecruitingPhase 2
CAR T-cell therapy made locally for B-cell blood cancers
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
Pittsburgh, PennsylvaniaAges 18–79 - NCT05282095Recruiting
Study how HPV changes affect outcomes in CIN2
This study follows women with an early abnormal cervix cell change (CIN2/CIN2-3) to see how HPV DNA “integration” relates to whether the condition improves or worsens. It may help doctors better predict prognosis and guide safer monitoring, especially if you want to become pregnant.
Fuzhou, FujianAges Up to 45 years - NCT05282108Recruiting
Generic imatinib vs Glivec for newly diagnosed CML
This trial studies whether a generic version of imatinib (Carcemia®) works as well and is as safe as Glivec® in real-life care for people newly diagnosed with chronic phase chronic myeloid leukemia (CML). It may help confirm that the generic option is effective for controlling the disease.
CairoAges 18 years+ - NCT05283044Recruiting
Precision medicine testing for advanced, hard-to-remove cancers
This study helps doctors use more individualized (precision) treatment choices for people with certain advanced cancers. You may be offered study care based on your cancer details, aiming to improve treatment decisions.
BayonneAges 18 years+ - NCT05283226RecruitingPhase 2
Oral anti-cancer pill plus paclitaxel after immunotherapy failure
This Phase 2 trial studies an oral study drug (NRC-2694-A) given with paclitaxel to treat head and neck squamous cell cancer that has come back or spread after immunotherapy. It tests whether this combination is safer and works better than expected for people whose cancer progressed on immune checkpoint inhibitors.
Fullerton, CaliforniaAges 18 years+ - NCT05283330RecruitingPhase 1
Tested 212Pb imaging drug for certain advanced GRPR tumors
This early-phase study tests how safe and tolerable an experimental radiation drug is for adults with certain advanced or metastatic cancers that show a target called GRPR. Doctors will also use special scans to confirm the tumor has the target so the treatment can be delivered to the right place.
Chicago, IllinoisAges 18 years+ - NCT05283993Recruiting
Hospital study following people with plasma cell disorders
This is a hospital-based study that follows people with plasma cell disorders to better understand these conditions. It mainly gathers information from patients who are confirmed to have one of several related diseases.
BeijingAges Any age - NCT05284552RecruitingPhase 2
Tinzaparin blood-thinner and biomarkers after ovarian cancer surgery
This Phase 2 study tests whether the blood thinner tinzaparin used after neoadjuvant treatment can change blood markers (“biomarkers”) in people with certain stages of ovarian cancer. It aims to understand if tinzaparin affects the body’s cancer-related signals, which could help future treatment decisions.
Eksjö, EksjöAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,669 recruiting oncology studies from the U.S. registry right now, out of 31,797 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.